• LAST PRICE
    3.3600
  • TODAY'S CHANGE (%)
    0.0000 (0.0000%)
  • Bid / Lots
    3.2300/ 2
  • Ask / Lots
    3.6200/ 1
  • Open / Previous Close
    0.0000 / 3.3600
  • Day Range
    ---
  • 52 Week Range
    Low 2.7200
    High 7.9700
  • Volume
    ---
    below average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Monday's close: 3.2
TimeVolumeTARA
09:32 ET2083.21
09:39 ET2093.1952
09:56 ET45733.28
10:12 ET2003.29
10:19 ET1003.29
10:26 ET12003.31
10:33 ET1003.31
10:44 ET1003.33
10:50 ET2603.3047
10:53 ET3003.35
11:02 ET1003.35
01:26 ET1003.3999
02:54 ET1003.37
03:21 ET1003.3601
03:59 ET6003.36
Data delayed at least 15 minutes.
0 New Today
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesTARA
Protara Therapeutics Inc
38.1M
-0.9x
---
United StatesCGTX
Cognition Therapeutics Inc
38.8M
-2.0x
---
United StatesHEPA
Hepion Pharmaceuticals Inc
37.0M
-0.8x
---
United StatesELDN
Eledon Pharmaceuticals Inc
37.8M
-1.0x
---
United StatesACHV
Achieve Life Sciences Inc
35.2M
-1.1x
---
United StatesTCON
TRACON Pharmaceuticals Inc
36.4M
-1.1x
---
As of 2022-10-05

Company Information

Protara Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company is focused on identifying therapies for the treatment of cancer and rare diseases. The Company's pipeline includes TARA-002 and IV Choline Chloride. The Company's lead product pipeline is TARA 002 for the treatment of non-muscle invasive bladder cancer (NMIBC) and Lymphatic Malformations (LMs). TARA 002 is a cellular therapy based on OK-432, also known as Picibanil, which is derived from a genetically distinct strain of Streptococcus Pyogenes. IV choline chloride is an investigational, intravenous (IV) phospholipid substrate replacement therapy, which is in development for patients receiving parenteral nutrition (PN) who have intestinal failure-associated liver disease (IFALD).

Contact Information

Headquarters
345 Park Avenue South, 3Rd FloorNEW YORK, NY, United States 10010
Phone
646-844-0337
Fax
302-655-5049

Executives

Independent Chairman of the Board
Luke Beshar
President, Chief Executive Officer, Chief Financial Officer, Director
Jesse Shefferman
Chief Scientific Operations Officer
Jacqueline Zummo
Senior Vice President - Investor Relations and Corporate Affairs
Justine O'Malley
Chief Medical Officer
Jathin Bandari

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$38.1M
Revenue (TTM)
$0.00
Shares Outstanding
11.3M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
0.94
EPS
$-3.58
Book Value
$14.41
P/E Ratio
-0.9x
Price/Sales (TTM)
---
Price/Cash Flow (TTM)
---
Operating Margin
---
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.